Geron received PATENT today. It sure seems to both be a precursor to use of Immetalstat as well as provide an independent metric to warn patients they may have cancer well before they even have symptoms. Who wouldn't take this test which I understand is non-intrusive?
IMHO this is better than what took Geron over $60/share in 2000.
IMHO
United States Patent 8,222,392
July 17, 2012
Kit for detection of telomerase reverse transcriptase nucleic acids
Abstract
The invention provides compositions and methods related to human telomerase reverse transcriptase (hTRT), the catalytic protein subunit of human telomerase. The polynucleotides and polypeptides of the invention are useful for diagnosis, prognosis and treatment of human diseases, for changing the proliferative capacity of cells and organisms, and for identification and screening of compounds and treatments useful for treatment of diseases such as cancers.
This is great news. I hope it can produce income soon.
Geron up 12 cents to closed at $1.69 on good volume of 1,433,755 shares. The three month avg. volume is 714,836 shares. Also STEM's good news should make Geron's stem cell property more valuable.
ACTC should have gone up on STEM's news, but it closed down a little at 0.0849 on 8.2 million shares. The three month avg. volume is 5.3 million shares.
AAPL up just a little at $606.94 on 10.5 million shares. The three month avg. is 17.5 million shares. The earnings date is July 26th.
Good luck in this rigged casino,
No comments:
Post a Comment